ARTICLE 33-06
REPORTABLE CONDITIONS

Chapter
33-06-01 Conditions Designated as Reportable
33-06-02 Reporting
33-06-03 Health Officer Investigation
33-06-04 Control of Specific Diseases
33-06-05 School Immunization Requirements
33-06-05.1 General Provisions
33-06-05.2 Students With Significant Contagious Diseases
33-06-05.3 Employees With Significant Contagious Diseases
33-06-05.4 Treatment of Independent Contractors With Significant Contagious Diseases
33-06-05.5 Relations With the Public
33-06-05.6 Education
33-06-06 Food Handlers [Repealed]
33-06-07 Laboratory Specimens for Carriers of Disease
33-06-08 Isolation Requirements
33-06-09 Common Carriers Federal Regulation Adopted and Shipment of Birds of the Psittacine Family
33-06-10 Disinfection
33-06-11 [Reserved]
33-06-12 [Reserved]
33-06-13 [Reserved]
33-06-14 [Reserved]
33-06-15 Preparation of Bodies and Transportation
33-06-16 Newborn Screening Program

CHAPTER 33-06-01
CONDITIONS DESIGNATED AS REPORTABLE

Section
33-06-01-01 Reportable Conditions

33-06-01-01. Reportable conditions.

All reports and information concerning reportable conditions are confidential and not open to inspection. The following designated reportable conditions must be reported to the state department of health by the persons designated in chapter 33-06-02. If any reportable condition is designated by an asterisk, an appropriate sample or isolate must be submitted to the division of microbiology (public health laboratory) in addition to the required report.

1. Anthrax*.
2. Arboviral infection.
3. Botulism*.
4. Brucellosis*.
5. Campylobacter enteritis*.
6. Cancer, all malignant and in situ carcinomas; in addition, all benign cancers of the central nervous system, pituitary gland, pineal gland, and craniohypophyseal duct. Carcinoma in situ of the cervix is not collected. Basal or squamous cell carcinoma is not collected unless diagnosed in the labia, clitoris, vulva, prepuce, penis, or scrotum.
7. All CD4 test results.
8. Chickenpox (varicella).
10. Cholera*.
11. Clostridium perfringens intoxication*.
12. Coccidioidomycosis*.
15. Diphtheria*.
16. E. coli, shiga toxin-producing*.
17. Enterococcus, vancomycin resistant (VRE)*.
18. Foodborne or waterborne outbreaks.
19. Giardiasis.
20. Glanders*.
22. Hantavirus*.
23. Haemophilus influenzae infection (invasive infection with haemophilus influenzae isolated from blood, cerebral spinal fluid, or other normal sterile site)*.
24. Hemolytic uremic syndrome.
25. Hepatitis (specify type).
26. Human immunodeficiency virus (HIV) infection, including acquired immunodeficiency syndrome (AIDS)*. (Any positive HIV test result.)
27. Human immunodeficiency virus (HIV) nucleic acid test result (detectable or nondetectable).
28. Human immunodeficiency virus (HIV) rapid screens (positive only).
29. Influenza.
30. Laboratory incidences involving the possible release of category A bioterrorism agents or novel influenza viruses into the laboratory environment.
31. Lead blood level greater than or equal to 10 ug/dl.
32. Legionellosis.
33. Listeriosis*.
34. Lyme disease.
35. Malaria*.
36. Measles (rubeola)*.
37. Melioidosis*.
38. Meningitis, bacterial (all bacterial species isolated from cerebrospinal fluid)*.
39. Meningococcal disease (invasive infection with neisseria meningitidis isolated from blood, cerebral spinal fluid, or other normal sterile site)*.
40. Mumps.
41. Nipah viral infections*.
42. Nosocomial outbreaks in institutions.
43. Organisms with reduced susceptibility to carbapenem* (ex. klebsiella pneumonia carbapenemase [KPC], carbapenem-resistant enterobacteriaceae [CRE], etc.).
44. Pertussis*.
45. Plague*.
46. Poliomyelitis*.
47. Pregnancy in a person infected with hepatitis B or HIV.
48. Psittacosis.
49. Q fever*.
50. Rabies (animal or human*).
51. Rocky Mountain spotted fever.
52. Rubella*.
53. Salmonellosis*.
54. Scabies outbreaks in institutions.
55. Severe acute respiratory syndrome (SARS)*.
56. Shigellosis*.
57. Smallpox*.
58. Staphylococcus aureus, methicillin resistant (MRSA), invasive sites only - excluding urine*.
59. Staphylococcus aureus, vancomycin resistant and intermediate resistant (VRSA and VISA)*.
60. Staphylococcus enterotoxin B intoxication*.
61. Streptococcal infections (invasive infection of streptococcus group A or B or streptococcus pneumoniae isolated from blood, cerebral spinal fluid, or other normal sterile site)*.
62. Syphilis.
63. Tetanus.
64. Tickborne diseases*.
65. Tickborne hemorrhagic fevers.
66. Toxic shock syndrome*.
67. Trichinosis.
68. Tuberculosis (tuberculosis disease caused by mycobacterium tuberculosis or mycobacterium bovis)*.
69. Tularemia*.
70. Tumors of the central nervous system.
71. Typhoid fever*.
72. Unexplained critical illness or death in an otherwise healthy person.
73. Unusual cluster of severe or unexplained illnesses or deaths.
74. Viral hemorrhagic fevers.
75. Weapons of mass destruction suspected event.
76. Yellow fever*.
77. Vibriosis*.

History: Amended effective May 1, 1984; December 1, 1986; January 1, 1988; January 1, 1989; October 1, 1990; January 1, 1991; February 1, 1992; May 1, 1994; January 1, 1995; July 1, 1996; February 1, 2000; August 1, 2002; March 1, 2003; July 1, 2004; April 1, 2007; January 1, 2011.

General Authority: NDCC 23-07-01
Law Implemented: NDCC 23-07-01